This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
ABSTRACT
BACKGROUND AND PURPOSE: Identifying patients with multiple sclerosis (pwMS) at higher risk of clinical progression is essential to inform clinical management. We aimed to build prognostic models using machine learning (ML) algorithms predicting long-term clinical outcomes based on a systematic mapping of volumetric, radiomic, and macrostructural disconnection features from routine brain MRI scans of pwMS.
MATERIALS AND METHODS: In this longitudinal monocentric study, 3T structural MRI scans of pwMS were retrospectively analyzed. Based on a ten-year clinical follow-up (average duration=9.4±1.1 years), patients were classified according to confirmed disability progression (CDP) and cognitive impairment (CI) as assessed through the Expanded Disability Status Scale (EDSS) and the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS) battery, respectively. 3D-T1w and FLAIR images were automatically segmented to obtain volumes, disconnection scores (estimated based on lesion masks and normative tractography data), and radiomic features from 116 gray matter regions defined according to the Automated Anatomical Labelling (AAL) atlas. Three ML algorithms (Extra Trees, Logistic Regression, and Support Vector Machine) were used to build models predicting long-term CDP and CI based on MRI-derived features. Feature selection was performed on the training set with a multi-step process, and models were validated with a holdout approach, randomly splitting the patients into training (75%) and test (25%) sets.
RESULTS: We studied 177 pwMS (M/F = 51/126; mean±SD age: 35.2±8.7 years). Long-term CDP and CI were observed in 71 and 55 patients, respectively. Regarding the CDP class prediction analysis, the feature selection identified 13-, 12-, and 10-feature subsets obtaining an accuracy on the test set of 0.71, 0.69, and 0.67 for the Extra Trees, Logistic Regression, and Support Vector Machine classifiers, respectively. Similarly, for the CI prediction, subsets of 16, 17, and 19 features were selected, with 0.69, 0.64, and 0.62 accuracy values on the test set, respectively. There were no significant differences in accuracy between ML models for CDP (p=0.65) or CI (p=0.31).
CONCLUSIONS: Building on quantitative features derived from conventional MRI scans, we obtained long-term prognostic models, potentially informing patients’ stratification and clinical decision-making.
ABBREVIATIONS: MS, multiple sclerosis; pwMS, people with MS; HC, healthy controls; ML, machine learning; DD, disease duration; EDSS, Expanded Disability Status Scale; TLV, total lesion volume; CDP, confirmed disability progression; CI, cognitive impairment; BICAMS, Brief International Cognitive Assessment of Multiple Sclerosis.
Footnotes
M.P. discloses travel/meeting expenses from Novartis, Janssen, Roche and Merck; speaking honoraria from HEALTH&LIFE S.r.l., AIM Education S.r.l., Biogen, Novartis and FARECOMUNICAZIONE E20, honoraria for consulting services and advisory board participation from Biogen, research grants from Baroni Foundation and the Italian Ministry of University and Research (PRIN 2022LP5X2E); L.U. discloses honorarium from the European Congress of Dentomaxillofacial Radiology; A.C. disclosed research grants from ECTRIMS-MAGNIMS and Almirall, travel/meeting expenses from Novartis, Janssen, Roche and Merck and speaking honoraria from Merk, BMS, Biogen, Novartis, Roche and Almirall; M.M. has received financial support by the MUR PNRR Extended Partnership (MNESYS no. PE00000006, and DHEAL-COM no. PNC-E3-2022-23683267), research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck, salary as Assistant Editor of Neurology, and honoraria from Abbvie, Biogen, BMS Celgene, Ipsen, Jansenn, Merck, Novartis, Roche, and Sanofi-Genzyme; S.C. has served on scientific advisory board for Amicus Therapeutics, has received speaker honoraria from Sanofi and research grants from Fondazione Italiana Sclerosi Multipla and Telethon; G.P. has received research grants from ECTRIMS (2022), MAGNIMS (2020), and ESNR (2021). The remaining authors have nothing to disclose.
- © 2025 by American Journal of Neuroradiology